Biomarker and Imaging Study to assess the ability of high doses rosuvastatin to decrease artherosclerosis in coronary arteries.
Recruiting
- Conditions
- Coronary artery disease
- Registration Number
- NL-OMON24500
- Lead Sponsor
- Erasmus Medical center (Thoraxcenter)
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
1. More than 18 years old;
2. Written informed consent;
Exclusion Criteria
1. Braunwald class IA, IIA, IIIA (unstable angina caused by non-cardiac illness);
2. Women who are pregnant or women of childbearing potential who do not use adequate contraception;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective of this clinical trial is to determine whether 40 mg rosuvastatin during 12 months decreases necrotic core as assessed by IVUS - VH at 52 weeks.
- Secondary Outcome Measures
Name Time Method To determine whether rosuvastatin reduces lipid core as assessed by LipiScan at 52 weeks.